Earnings Insights · Insulet (PODD) · Q3 FY2026
Insulet (PODD) Q3 FY2026: Insulet Q3 2026 Earnings: International Growth and Margin Expansion Offset a Slower 2027 Outlook
By AlgovestIQ ResearchPublished
Read Insulet’s results announcement (Form 8-K, filed Nov 4, 2026)
Key earnings findings
Insulet (PODD) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed
- Insulet reported Q3 FY2026 revenue of $842.0M against the $832.6M analyst estimate, a 1.1% beat, and EPS of $1.99 against the $1.59 analyst estimate, a 25.2% beat.
- PODD closed at $165.02 on Nov 4, 2026, up 6.6% from $154.86 on Nov 3, 2026, the last close before the results were released.
- Insulet reported third-quarter revenue of $842.0M, up 19.2% year over year, while GAAP diluted EPS rose to $2.03 from $1.24.
Sources: Insulet results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references
Did Insulet beat earnings expectations?
- EPS has beaten the estimate in all 8 of the most recent reported quarters on record.
- Revenue surprise across the last 8 reported quarters has ranged from 1.1% to 5.7%.
Reported figures against analyst estimates, compiled from AlgovestIQ data.
Insulet reported third-quarter revenue of $842.0M, up 19.2% year over year, while GAAP diluted EPS rose to $2.03 from $1.24. Adjusted diluted EPS increased 59.9% to $1.99 as operating leverage, manufacturing productivity, and lower bonus accruals lifted profitability.
The quarter reinforced the strength of Omnipod demand, particularly outside the U.S., and prompted Insulet to narrow its full-year revenue outlook toward the high end of its prior range. The more consequential update, however, was management’s preliminary view that 2027 growth will moderate to modestly below its previous mid-teens framework as international comparisons become harder, price-mix benefits fade, and new competitors enter the automated insulin delivery market.
Earnings Snapshot
| Metric | Reported | Change |
|---|---|---|
| Total revenue | $842.0M | Up 19.2% |
| Constant-currency revenue growth | 19.6% | — |
| Total Omnipod revenue | $836.6M | Up 19.7% |
| U.S. Omnipod revenue | $570.4M | Up 14.7% |
| International Omnipod revenue | $266.2M | Up 31.7%; up 33.0% constant currency |
| Drug Delivery revenue | $5.5M | Down 22.7% |
| Gross profit | $632.1M | Up from $510.1M |
| GAAP gross margin | 75.1% | — |
| GAAP operating income | $189.8M | Up from $117.7M |
| GAAP operating margin | 22.5% | Up 590 basis points |
| Adjusted operating income | $185.2M | Up from $120.7M |
| Adjusted operating margin | 22.0% | Up 490 basis points |
| Net income | $141.1M | Up from $87.6M |
| GAAP diluted EPS | $2.03 | Up from $1.24 |
| Adjusted diluted EPS | $1.99 | Up 59.9% |
The Bigger Story
Insulet remains in a favorable operating position heading into 2027, with its customer base growing more than 20% globally and international Omnipod revenue expanding at a 33% constant-currency rate. The company also showed that profitability can rise faster than revenue while it continues investing in its sales organization, customer support, manufacturing capacity, and product pipeline.
But the investment discussion is shifting from 2026 execution to the durability of growth in 2027. Management expects total-company growth next year to be modestly below the mid-teens framework it discussed previously, citing a tougher revenue comparison, reduced international price-mix benefits, the timing of product launches, and a more competitive market.
That does not represent a change in Insulet’s long-term growth ambition, but it does lower the near-term baseline. Management expects to guide U.S. growth toward the lower end of its prior 9% to 14% framework, while international growth is expected to slow meaningfully from 2026 levels.
Revenue and Operating Performance
Total revenue increased 19.2% to $842.0M, or 19.6% in constant currency. Omnipod products accounted for $836.6M of quarterly revenue, or virtually all of the company’s sales, making the business’s reliance on its core insulin delivery platform clear.
U.S. Omnipod revenue rose 14.7% to $570.4M. Management attributed the increase to continued demand across both type 1 and type 2 diabetes, with the U.S. customer base growing in the high teens. However, new customer starts in the U.S. were flat year over year, and management said pricing was slightly negative during the quarter, though still flat year to date.
International Omnipod revenue was the primary growth engine, increasing 31.7% as reported and 33.0% in constant currency to $266.2M. The increase was driven mainly by volume growth and favorable price-mix realization as customers converted to Omnipod 5 and the company expanded into new markets.
International results also included a 250-basis-point benefit from reserve adjustments. Those adjustments included approximately $3M in France, primarily related to a clawback accrual, and about $2M in Canada from reserve releases and updated program assumptions. These items helped reported international growth, although management continued to describe underlying demand as healthy.
Drug Delivery revenue fell 22.7% to $5.5M. The segment remains small relative to Omnipod and is not currently a material contributor to the company’s growth profile.
Management said global new customer starts grew in the low single digits during the quarter and in the low double digits year to date. More than 85% of Omnipod new starts came from multiple daily injection users, supporting Insulet’s argument that it is expanding the automated insulin delivery category rather than relying only on conversions from competing pumps.
Profitability and Margins
Profitability increased substantially faster than revenue. GAAP operating income rose to $189.8M from $117.7M, lifting GAAP operating margin 590 basis points to 22.5%. Adjusted operating income increased to $185.2M, with adjusted operating margin rising 490 basis points to 22.0%.
Adjusted gross margin increased 200 basis points to 74.2%, which management attributed to productivity gains across its global manufacturing operations. The company has been investing in manufacturing scale and capacity, and the quarter suggests those investments are beginning to produce better unit economics.
Adjusted operating margin also benefited from lower annual employee bonus accruals. That aided the quarter’s 490-basis-point year-over-year expansion and should be considered alongside the underlying gross-margin improvement when assessing the sustainability of the earnings acceleration.
GAAP gross margin was 75.1%, above the adjusted 74.2% figure because GAAP results included a $7.2M benefit from adjustments to estimated warranty and related costs associated with voluntary medical device corrections issued earlier in the year. The adjusted figures exclude this benefit.
Net income increased to $141.1M from $87.6M, while adjusted net income rose 57.2% to $138.0M. Adjusted EPS increased nearly 60% to $1.99, outpacing revenue growth as gross-margin improvement and operating leverage more than offset higher spending on R&D, sales capacity, market development, and customer support.
Demand, Customers and Pricing
Insulet ended the quarter with a global customer base that management said grew more than 20% from the prior-year period. That installed base is important because Omnipod is a recurring consumables business, with users requiring replacement Pods over time.
Management said utilization remained stable and customer consumption growth broadly tracked customer-base growth. Those trends support the quality of revenue growth, although the flatter new-start result in the U.S. remains a point to monitor.
Type 2 diabetes is the more important execution issue. More than 40% of U.S. new customer starts came from type 2 users, but management had previously identified elevated attrition in that population. Insulet said type 2 retention improved modestly in the third quarter after it tightened sample governance, added clinical retention specialists, adjusted sales incentives to include retention metrics, and improved onboarding and support during the first 90 days.
The company’s Omnipod Discover engagement platform reached more than 35,000 users and 5,000 healthcare professionals following its full U.S. release. Management said the limited rollout showed stronger retention and improved time-in-range results, but described the platform’s financial contribution as early-stage and expects any more meaningful impact in 2027 and beyond.
Management also said it has not observed an adverse effect from increased GLP-1 use on type 2 new starts, viewing GLP-1 therapies as complementary to insulin treatment rather than a substitute for insulin delivery systems.
On pricing, management expects positive U.S. pricing for the full year despite a slight decline in the third quarter. The company has completed one of its three pharmacy benefit manager contract negotiations for 2027 and expects to finalize the remaining two in coming weeks. Management’s goal is to maintain broad pharmacy-channel access and stable pricing.
What is Insulet’s guidance for FY 2026?
Insulet narrowed its full-year 2026 outlook toward the high end of its prior ranges.
| FY 2026 Guidance | Current Outlook |
|---|---|
| U.S. Omnipod revenue growth | 17.5% to 18.5% constant currency |
| International Omnipod revenue growth | 32% to 33% constant currency |
| Total Omnipod revenue growth | 21.5% to 22.5% constant currency |
| Drug Delivery revenue growth | Approximately negative 40% |
| Total revenue growth | 21% to 22% constant currency |
| Adjusted operating margin expansion | Approximately 150 basis points |
| Adjusted EPS growth | More than 30% |
| Free cash flow | Approximately $275M |
Management expects foreign exchange to add about 100 basis points to full-year total-company and total Omnipod growth, with a roughly 300-basis-point benefit to international growth.
For the fourth quarter, management expects total-company revenue growth of 13.5% to 17.0% and total Omnipod growth of 13.0% to 16.5%. U.S. Omnipod growth is expected at 10.0% to 13.5%, while international Omnipod growth is expected at 21.0% to 24.0%.
The lower fourth-quarter growth range reflects a more difficult year-over-year comparison, particularly in the U.S., rather than a reported deterioration in the installed base or utilization trends.
For 2027, management did not provide formal guidance. It said total-company growth is now expected to be modestly below its previous mid-teens framework. The company cited a larger revenue base, a tougher international comparison, less price-mix benefit as Omnipod 5 conversions mature, several large country launches being anniversaryed, limited near-term contribution from new product launches, and a more competitive market.
Management continues to target an Omnipod 6 launch in 2027, having submitted the second and final 510(k). It also expects to submit its fully closed-loop type 2 system for 510(k) clearance in 2027, with a planned launch in 2028.
Balance Sheet, Cash Flow and Capital
Insulet ended September with $584.4M in cash and cash equivalents, down from $716.1M at year-end. Long-term debt was $943.0M, while the current portion of long-term debt was $19.1M.
During the quarter, the company increased its corporate revolver to $750M and refinanced its Term Loan B, lowering the interest rate by 25 basis points. Management said the entire $750M revolver remained available at quarter-end.
Nine-month operating cash flow was $325.7M, down from $386.0M in the prior-year period. Capital expenditures doubled to $113.9M from $56.5M as Insulet invested in manufacturing capacity. As a result, nine-month free cash flow declined to $211.7M from $329.5M.
The board authorized a new $1B share repurchase program, and management expects to repurchase approximately $400M of stock in the fourth quarter using existing cash. The planned buyback is sizable relative to the company’s cash balance and comes while Insulet continues to invest in capacity, commercialization, and product development. Management believes its cash generation and liquidity are sufficient to support both priorities.
What Investors Should Watch
1. U.S. New Customer Starts and Type 2 Retention
The U.S. customer base continued to grow in the high teens, but new customer starts were flat year over year. Investors should watch whether Insulet’s revised sampling, onboarding, sales-incentive, and customer-support programs translate into better type 2 retention and renewed start growth.
2. International Growth Quality After Reserve Benefits
International revenue rose 33% in constant currency, but the quarter included a 250-basis-point benefit from reserve adjustments. The larger issue is whether customer growth can remain strong as Omnipod 5 conversion benefits and large-country launch contributions become less favorable in 2027.
3. 2027 Guidance and Competitive Pressure
Management expects to provide formal 2027 guidance in February. That outlook will clarify how much growth moderation comes from conservative planning versus fundamental pressure from new automated insulin delivery competitors, lower international price-mix benefits, and a tougher comparison base.
4. Omnipod 6 Regulatory Progress and Launch Preparation
Omnipod 6 is central to Insulet’s competitive positioning in 2027. Management expects the system to offer 40% fewer boluses and cited 76% time in range in adults and adolescents with type 1 diabetes. Regulatory timing, manufacturing readiness, and commercial adoption will determine how much it contributes next year.
5. Cash Flow After Buybacks and Capacity Spending
Management expects approximately $275M of 2026 free cash flow while planning a $400M fourth-quarter repurchase. Investors should monitor whether free cash flow rebounds as capital spending normalizes, particularly given ongoing manufacturing expansion and a balance sheet that carries nearly $1B of long-term debt.
AlgovestIQ Takeaway
Insulet delivered a strong third quarter. Revenue growth remained near 20%, international execution was notably strong, and adjusted operating margin expanded nearly five percentage points. The business also continues to add customers at a greater than 20% global rate, preserving the recurring-revenue foundation that supports its premium growth profile.
The quarter’s most favorable operating signal was the combination of growth and margin expansion. Insulet is spending more on commercial capabilities, customer support, manufacturing capacity, and innovation, yet adjusted EPS grew 59.9%. That indicates meaningful operating leverage, although lower bonus accruals and a favorable medical-device-correction adjustment also aided reported profitability.
The less favorable development is the reset in expectations for 2027. Management still expects top-tier growth, but its preliminary framework points to a material moderation from 2026 as international growth normalizes and competition increases. That shift is particularly important because international revenue has been the company’s fastest-growing business and a major source of price-mix benefit.
The central investment question is whether Insulet can convert its large and growing installed base, expanded sales force, customer-engagement platform, and Omnipod 6 launch into sustained category leadership as the market becomes more crowded. Evidence of improving type 2 retention, stable U.S. access and pricing, and continued international customer growth would strengthen that case. Conversely, weak U.S. new starts, further attrition issues in type 2, or a sharper-than-expected international slowdown would make the 2027 growth reset more consequential.
How did PODD stock react?
PODD closed at $165.02 on Nov 4, 2026, up 6.6% from $154.86 on Nov 3, 2026, the last close before the results were released.
| Session | Close | Change |
|---|---|---|
| Nov 3, 2026 (before release) | $154.86 | — |
| Nov 4, 2026 | $165.02 | +6.6% |
| Nov 5, 2026 | $156.12 | +0.8% |
Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.
More from this earnings season
- EWEdwards Lifesciences Q3 2026 Earnings: TAVR and TMTT Strength Drive Higher Full-Year OutlookNov 4, 2026
- TMDXTransMedics Q3 2026 Earnings: Revenue Growth Accelerates as Heart, Liver and Logistics Gain ShareNov 5, 2026
- SYKStryker Q3 2026 Earnings: Orthopaedics Slowdown Overshadows Strong MedSurg GrowthOct 29, 2026
- DXCMDexcom Q3 2026 Earnings: Margin Expansion and U.S. Growth Offset Slower International SalesOct 29, 2026
- BSXBoston Scientific Q3 2026 Earnings: Cyberattack and Rhythm-Management Pressures Reset 2027 OutlookOct 28, 2026
References
- Management commentary, analyst questions and outlook discussed on the call. Source: Insulet Q3 FY2026 earnings call transcript, as of Nov 4, 2026.
- Reported results, segment figures and guidance from the company's results announcement. Source: Insulet Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 4, 2026.
- Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 4, 2026.
AI-generated analysis based on company-reported earnings data and earnings-call materials. Every reported figure is checked against Insulet's earnings release and call transcript before publication. Not investment advice.